Company

Beat AML

As of the edition of 20 October 2026, Beat AML runs 9 drugs; it is on route A at 5 targets and on route B at 0 targets.

Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.

Drugs by status

StatusCount
Active2
Went quiet1
Stopped6
Total9

Where it needs a new molecule

Route A at 5 targets, route B at 0 targets.

Three of its 5 rows, by target and route
TargetRoute
CD33 Myeloid cell surface antigen CD33Route A
CD200 OX-2 membrane glycoproteinRoute A
MCL1 Induced myeloid leukemia cell differentiation protein Mcl-1Route A

All 5 rows on route A or B

In the product

5 company-target rows on route A or B; 2 are not shown here, and no score is.